Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $41
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice Target
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $39 to $41.
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $39 to $41.